WO2023120370A1 - Composition orale et procédé pour réduire au minimum l'amertume résultant de l'ergothionéine ou d'un sel de celle-ci et l'odeur résultant de la vitamine e - Google Patents

Composition orale et procédé pour réduire au minimum l'amertume résultant de l'ergothionéine ou d'un sel de celle-ci et l'odeur résultant de la vitamine e Download PDF

Info

Publication number
WO2023120370A1
WO2023120370A1 PCT/JP2022/046218 JP2022046218W WO2023120370A1 WO 2023120370 A1 WO2023120370 A1 WO 2023120370A1 JP 2022046218 W JP2022046218 W JP 2022046218W WO 2023120370 A1 WO2023120370 A1 WO 2023120370A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
ergothioneine
salt
component
derived
Prior art date
Application number
PCT/JP2022/046218
Other languages
English (en)
Japanese (ja)
Inventor
亜由太 船木
恵 江口
未来 杉崎
Original Assignee
サントリーホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントリーホールディングス株式会社 filed Critical サントリーホールディングス株式会社
Publication of WO2023120370A1 publication Critical patent/WO2023120370A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to oral compositions.
  • the present invention also relates to a method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from vitamin E in an oral composition containing ergothioneine or a salt thereof and vitamin E.
  • Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability.
  • Patent Document 1 reports immune response activation cytokine production promotion action and the like.
  • ergothioneine has attracted attention as a food, cosmetic, and pharmaceutical product because of its various physiological activities.
  • Vitamin E is a fat-soluble vitamin with antioxidant properties. Vitamin E has various physiological activities such as blood flow improving action, arteriosclerosis preventing or improving action, and LDL (bad cholesterol) reducing action, and is widely used in foods, beverages, pharmaceuticals, feeds, and the like. there is
  • ergothioneine since ergothioneine has useful physiological activities, foods such as supplements containing ergothioneine or salts thereof are useful for maintaining or promoting health.
  • vitamin E also has useful physiological activities as described above, various useful effects can be expected by ingesting an oral composition containing ergothioneine or a salt thereof and vitamin E. it is conceivable that.
  • ergothioneine or a salt thereof has a peculiar flavor, particularly a bitterness that stings the tongue, and there is room for improvement in making it an oral composition.
  • vitamin E has an unpleasant flavor, specifically, a peculiar smell.
  • An object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and vitamin E, while suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from vitamin E.
  • Another object of the present invention is to provide a method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from vitamin E.
  • the present inventors found that by combining ergothioneine or a salt thereof and vitamin E in a specific ratio, bitterness derived from ergothioneine or a salt thereof and vitamin E derived from It was found that the odor can be suppressed.
  • the present invention includes the following oral compositions and the like.
  • component (B) is ⁇ -tocopherol and/or ⁇ -tocopherol.
  • [5] The composition according to any one of [1] to [4] above, which contains an edible oil.
  • component (B) is derived from vegetable oil.
  • [7] The composition according to any one of [1] to [6] above, which is a food or drink.
  • [8] The following components (A) and (B): Method for suppressing bitterness derived from component (A) and odor derived from component (B) in an oral composition containing (A) ergothioneine or a salt thereof and (B) at least one vitamin E Derived from ergothioneine or a salt thereof, wherein the weight ratio ((B)/(A)) of component (B) (in terms of vitamin E) to component (A) (in terms of ergothioneine) is adjusted to 1 to 27 A method for suppressing bitterness and odor derived from vitamin E.
  • an oral composition containing ergothioneine or a salt thereof and vitamin E while suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from vitamin E. Further, according to the present invention, it is possible to provide a method for suppressing the bitterness derived from ergothioneine or its salts and the odor derived from vitamin E.
  • the oral composition of the present invention contains (A) ergothioneine or a salt thereof (component (A)), and (B) at least one vitamin E (component (B)), and component (A) ( The weight ratio ((B)/(A)) of component (B) (in terms of vitamin E) to ergothioneine) is 1-27.
  • Ergothioneine is a kind of sulfur-containing amino acid.
  • ergothioneine is preferably L-ergothioneine.
  • the salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for food and drink, and may be either an acid salt or a basic salt.
  • Acid salts include, for example, inorganic salts such as hydrochlorides, sulfates, nitrates, phosphates; Examples include organic acid salts such as acid salts and propionate salts.
  • Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts;
  • Ergothioneine or a salt thereof is not at all limited by its form, production method, and the like. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from natural products. A large amount of L-ergothioneine is contained in Golden/Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), which is a mushroom belonging to the genus Pleurotus of the Oysteraceae family.
  • Golden/Yellow Oyster Mushroom scientific name: Pleurotus cornucopiae var. citrinopileatus
  • L-ergothioneine is found in white button mushrooms, crimini mushrooms, portabella mushrooms and other mushrooms (scientific name: Agaricus bisporus), gray oyster mushrooms (scientific name: Pleurotus ostreatus), shiitake mushrooms (scientific name: Lentinula edodes), maitake mushrooms (Scientific name: Grifola frondosa), Reishi (Scientific name: Ganoderma lucidum), Hericium erinaceus (Scientific name: Hericium erinaceus), Willow matsutake (Scientific name: Agrocybeaegerita), Chanterelle (Scientific name: Cantharellus cibarius), Porcini Name: Boletus edulis), morels ( It is also contained in mushrooms such as Morchella esculenta (scientific name: Morchella esculenta).
  • L-ergothioneine When L-ergothioneine is obtained from a natural product, it is preferably extracted from Pleurotus cornucopia. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
  • vitamin E refers to vitamin E and derivatives thereof. Vitamin E may be used individually by 1 type, and may be used in combination of 2 or more type.
  • vitamin E refers to tocopherols and tocotrienols.
  • tocopherol one or more selected from the group consisting of ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol and ⁇ -tocopherol can be used.
  • tocotrienol one or more selected from the group consisting of ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol and ⁇ -tocotrienol can be used.
  • Tocopherols, tocotrienols, and derivatives thereof may be d-, l-, or dl-forms, preferably d-forms.
  • vitamin E may be food or drink or pharmacologically acceptable ones, and examples thereof include tocopherol organic acid esters such as tocopherol acetate, tocopherol succinate, tocopherol linoleate, and tocopherol linolenate. .
  • vitamin E is preferably tocopherol and/or tocotrienol (vitamin E), preferably ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocotrienol, ⁇ -tocotrienol , ⁇ -tocotrienol and ⁇ -tocotrienol.
  • the vitamin E is more preferably tocopherol, still more preferably ⁇ -tocopherol and/or ⁇ -tocopherol, and particularly preferably d- ⁇ -tocopherol and/or d- ⁇ -tocopherol.
  • the vitamin E used in the present invention is not at all limited by its form, production method, and the like.
  • vitamin E chemically synthesized products may be used, and those extracted and purified from natural products may be used.
  • vitamin E can be blended into the composition using a raw material containing a large amount of vitamin E.
  • Edible fats and oils are examples of raw materials containing a large amount of vitamin E.
  • the oral composition of the present invention may contain an edible oil containing at least one vitamin E.
  • the oral composition of the present invention comprises an edible fat, and vitamin E may be part of the edible fat.
  • vitamin E may be partially or wholly incorporated into the oral composition as part of the edible oil.
  • vitamin E is preferably derived from edible fats and oils, and more preferably derived from vegetable fats and oils.
  • Vegetable oils and fats are oils and fats obtained by extracting and refining oils and fats contained in plants.
  • a vegetable oil is preferable as the vegetable oil.
  • Vegetable oils and fats also include those obtained by highly refining vitamin E extracted from plants to increase the vitamin E content.
  • Vegetable oils rich in vitamin E include soybean oil, cottonseed oil, rapeseed oil, safflower oil, sunflower oil, sesame oil, corn oil, rice oil, olive oil, grapeseed oil, and the like.
  • the oral composition of the present invention may contain vegetable oil.
  • a vegetable oil is included, and the vitamin E may be incorporated, in part or in whole, into the oral composition as part of the vegetable oil.
  • the vegetable oil preferably has a vitamin E content (in terms of vitamin E) of 10 to 90% by weight, more preferably 40 to 90% by weight, even more preferably 50 to 80% by weight. .
  • the weight ratio of (B) vitamin E (component (B)) in terms of vitamin E ((B )/(A)) is 1-27.
  • Ergothioneine or its salts have a bitter taste that stings the tongue.
  • vitamin E also has a peculiar odor.
  • the weight ratio ((B)/(A)) of component (B) (in terms of vitamin E) to component (A) (in terms of ergothioneine) is within the above range. With this, the bitterness derived from the component (A) can be suppressed, and the odor derived from the component (B) can also be suppressed.
  • the weight ratio ((B)/(A)) is preferably 2 or more, more preferably 2.5 or more, and preferably 26 or less, more preferably 16 or less.
  • the weight ratio ((B)/(A)) of component (B) (in terms of vitamin E) to component (A) (in terms of ergothioneine) is preferably 2 to 26, more preferably 2. 5-16.
  • the amount in terms of ergothioneine or a similar expression means the amount in the case of ergothioneine, and in the case of a salt of ergothioneine, the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.
  • the amount in terms of vitamin E or similar expressions mean the amount in the case of vitamin E, and the value in terms of vitamin E (tocopherol, tocotrienol) in the case of vitamin E derivatives. Specifically, when the vitamin E derivative is a tocopherol derivative, it is a value converted to tocopherol, and when the vitamin E derivative is a tocotrienol derivative, it is a value converted to tocotrienol.
  • the amount of the vitamin E derivative in terms of vitamin E can be obtained by multiplying the number of moles of the derivative by the molecular weight of the tocopherol.
  • the number of moles of the derivative can be multiplied by the molecular weight of the tocotrienol to determine the amount of the derivative in terms of vitamin E.
  • the weight of vitamin E is the sum of these when two or more kinds of vitamin E are contained.
  • the content of ergothioneine or a salt thereof contained in the oral composition of the present invention is not particularly limited, and can be set according to its form and the like.
  • the content of ergothioneine or a salt thereof in the oral composition of the present invention is, in terms of ergothioneine, for example, preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and 1% by weight in the composition.
  • the above is more preferable, 50% by weight or less is preferable, 20% by weight or less is more preferable, and 10% by weight or less is even more preferable.
  • the content of ergothioneine or a salt thereof is preferably 0.1 to 50% by weight, more preferably 0.5 to 20% by weight, and 1 to 10% by weight in terms of ergothioneine in the composition of the present invention. is more preferred.
  • the content of ergothioneine can be measured by a high performance liquid chromatography (HPLC) method.
  • the content of vitamin E contained in the oral composition of the present invention is not particularly limited, and can be set according to its form and the like.
  • the content of vitamin E in the oral composition of the present invention, in terms of vitamin E may be, for example, 0.1% by weight or more, preferably 0.2% by weight or more, and 0.2% by weight or more.
  • the content of vitamin E in the oral composition of the present invention may be, for example, 0.1 to 90% by weight, 0.2 to 90% by weight, 0.2 to 90% by weight, in terms of vitamin E. 5 to 80% by weight or 1 to 80% by weight is preferred, 5 to 80% by weight is more preferred, and 10 to 60% by weight is even more preferred.
  • the content of vitamin E is the total content when two or more vitamin E compounds are contained. The content of vitamin E can be measured by HPLC method.
  • the content of ergothioneine or a salt thereof is preferably 1 to 100 mg, more preferably 2 to 50 mg, more preferably 5 to 25 mg in terms of ergothioneine per day for adults. more preferably 5 to 20 mg, particularly preferably 5 to 20 mg.
  • the content of vitamin E is preferably 1 to 900 mg, more preferably 5 to 900 mg, more preferably 10 to 500 mg in terms of vitamin E per day for adults. more preferably 20 to 300 mg, particularly preferably 30 to 120 mg.
  • Ergothioneine or its salts and vitamin E are compounds that are contained in natural products and foods and drinks and have been eaten. Therefore, from the viewpoint of safety, ergothioneine or its salts and vitamin E are considered to have few problems, for example, even if they are ingested every day. Effect of the Invention According to the present invention, it is possible to provide a composition that is highly safe, suppresses bitterness derived from ergothioneine or a salt thereof and odor derived from vitamin E, and is easy to ingest.
  • ergothioneine or a salt thereof is known to exhibit various physiological activities and health functions.
  • UV absorption effect, melanin production inhibitory effect, reactive oxygen species scavenging effect, elastase activity inhibitory effect, wrinkle formation inhibitory effect, skin sagging inhibitory effect, autophagy promoting effect, etc. are known. Therefore, the composition of the present invention is used for antioxidant, brain function improvement, anti-aging, eye disease, whitening, ultraviolet absorption, suppression of melanin production, elimination of reactive oxygen species, and inhibition of elastase activity. , for suppressing wrinkle formation, for suppressing skin sagging, for promoting autophagy, and the like.
  • Vitamin E is known to exhibit various health functions, such as antioxidant action, blood flow improvement action, prevention or improvement of arteriosclerosis, inhibition of oxidation of LDL cholesterol in blood, and prevention of destruction of red blood cells.
  • the composition of the present invention contains vitamin E, it can also be used to obtain the above effects exhibited by vitamin E.
  • compositions of the present invention can be applied for either therapeutic use (medical use) or non-therapeutic use (non-medical use).
  • Non-therapeutic is a concept that does not involve medical intervention, i.e. human surgery, treatment or diagnosis.
  • the composition of the present invention can be in the form of foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like.
  • the composition of the present invention may be a material or formulation that is used by being blended in foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like.
  • composition of the present invention is an oral composition.
  • oral compositions include food and drink, oral pharmaceuticals, quasi-drugs, and feeds, preferably food and drink or oral pharmaceuticals, and more preferably food and drink.
  • the composition of the present invention can contain optional additives and optional ingredients as long as the effects of the present invention are not impaired. These additives and ingredients can be selected according to the form of the composition, etc., and those generally usable for oral compositions such as food and drink, pharmaceuticals, quasi-drugs, and feeds can be used.
  • the composition of the present invention may consist of ergothioneine or a salt thereof and vitamin E's.
  • the oral composition of the present invention may contain, for example, edible oils and fats that do not contain vitamin E.
  • the form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
  • the oral composition of the present invention contains an edible oil (hereinafter sometimes referred to as component (C))
  • the edible oil preferably contains the above vitamin E-containing edible oil.
  • the weight of vitamin E in terms of vitamin E is 5 to 90% by weight with respect to 100% by weight of edible fats and oils (component (C)) in the composition. and more preferably 10 to 80% by weight.
  • the weight ratio of edible fats and oils (component (C)) to the weight of (A) ergothioneine or a salt thereof (component (A)) in terms of ergothioneine in the composition ( (C)/(A)) may be, for example, 3 to 200, may be 4 to 150, may be 5 to 100, preferably 5 to 90, more preferably 5 to 50, 5 ⁇ 40 is more preferred.
  • the weight of edible fats and oils is the sum total when two or more types of edible fats and oils are used.
  • the weight of edible oils and fats containing vitamin E includes the weight of vitamin E.
  • the composition of the present invention when the composition of the present invention contains an edible oil containing vitamin E, the composition contains vitamin E relative to the ergothioneine-equivalent weight of (A) ergothioneine or a salt thereof (component (A)) in the composition.
  • the weight ratio of the edible oil is, for example, preferably 3-90, more preferably 4-50, even more preferably 5-40.
  • composition of the present invention when used as a food or drink, ergothioneine or a salt thereof and vitamin E are blended with ingredients that can be used for food or drink (for example, food materials, food additives used as necessary). It can be used as various foods and drinks.
  • Food and drink are not particularly limited, and examples thereof include general food and drink, health food, health supplement, health drink, food with function claims, food for specified health use, and food and drink for sick people.
  • Health foods, health supplements, foods with function claims, foods for specified health use, etc. are, for example, fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, and drinks. It can be used as various formulation forms such as medicines and liquid foods.
  • composition of the present invention When the composition of the present invention is used as a drug or quasi-drug, for example, ergothioneine or a salt thereof and vitamin E are blended with a pharmacologically acceptable carrier, additives added as necessary, and the like. It can be used as pharmaceuticals or quasi-drugs in various dosage forms. Such carriers, additives, etc. may be those that can be used for pharmaceuticals or quasi-drugs and are pharmacologically acceptable. One or more of antioxidants, coloring agents and the like can be mentioned. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables and the like.
  • feed When the composition of the present invention is used as a feed, ergothioneine or a salt thereof and at least one vitamin E may be added to the feed.
  • Feed also includes feed additives. Examples of feeds include livestock feeds for cows, pigs, chickens, sheep, horses, etc.; small animal feeds for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc.;
  • Subjects to whom the composition of the present invention is ingested or administered are not particularly limited. Humans or non-human mammals are preferred, and humans are more preferred.
  • the method for producing the oral composition of the present invention is not particularly limited. can be produced by blending into the composition.
  • Weight ratio of component (B) (converted to vitamin E) to component (A) (converted to ergothioneine) in the preparation of an oral composition containing ergothioneine or a salt thereof and (B) at least one vitamin E By adjusting ((B)/(A)) to 1 to 27, it is possible to obtain an oral composition in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from vitamin E are suppressed. Adjustment of the said ratio can be performed by adjusting the compounding quantity of each component.
  • edible oils and fats containing the above-described vitamin E may be blended.
  • vitamin E may be dissolved in edible fats and oils that do not contain vitamin E and blended into the composition.
  • vitamin E may be partially or wholly incorporated into the oral composition as part of the edible oil.
  • the content of vitamin E in the edible oil is, for example, preferably 10 to 90% by weight, more preferably 40 to 90% by weight, More preferably 50 to 80% by weight.
  • the weight ratio of edible fats and oils (component (C)) to the weight of (A) ergothioneine or its salt (component (A)) in terms of ergothioneine ((C)/ (A)) is preferably 2 to 40, more preferably 3 to 30, even more preferably 4 to 20.
  • the present invention also includes the following methods.
  • Adjustment of the weight ratio can be performed by adding component (A) and/or component (B), for example.
  • ergothioneine or a salt thereof, vitamin E and preferred embodiments thereof are the same as those of the oral composition of the present invention described above.
  • the preferred range of the weight ratio ((B)/(A)) of component (B) (in terms of vitamin E) to component (A) (in terms of ergothioneine) is also the same as in the oral composition of the present invention.
  • bitterness derived from ergothioneine or a salt thereof and the odor derived from vitamin E can be suppressed by the above method, it may be combined with other bitterness suppression methods and/or odor suppression methods.
  • Other bitterness suppression methods or odor suppression methods include, for example, a method of adding a sweetening agent or a corrigent to a component having a bitter taste or odor, and a method of coating a component having a bitter taste or odor with sugar coating. , or a method of encapsulating and formulating.
  • Vitamin E is useful for suppressing the bitter taste of ergothioneine or its salt.
  • the present invention also includes use of (B) at least one vitamin E for (A) suppressing bitterness derived from ergothioneine or a salt thereof.
  • the amount of vitamin E used is such that the weight ratio ((B)/(A)) of (B) vitamin E (converted to vitamin E) to (A) ergothioneine or its salt (converted to ergothioneine) is 1 or more. is preferred, and an amount that makes the above weight ratio 1 to 27 is more preferred.
  • Ergothioneine or a salt thereof is useful for suppressing the odor of vitamin E.
  • the present invention also includes use of (A) ergothioneine or a salt thereof for suppressing the smell of (B) vitamin E.
  • the amount of ergothioneine or its salt used is such that the weight ratio ((B)/(A)) of (B) vitamin E (converted to vitamin E) to (A) ergothioneine or its salt (converted to ergothioneine) is 1 or more.
  • the amount is preferable, and the amount that makes the above weight ratio 1 to 27 is more preferable.
  • a range represented by “1-2” means from 1 to 2 and includes 1 and 2.
  • the upper limit and the lower limit may be any combination of ranges.
  • Raw materials used in the following evaluation tests are as follows.
  • Vitamin E-containing raw material Vegetable oil containing 60% by weight of d- ⁇ -tocopherol and mainly made from soybeans (vitamin E content: 60% by weight)
  • C1 and (C2) above contain only vitamin E as vitamin E.
  • Example 1 By mixing the raw materials (A) and (C1) in amounts shown in Table 1, oral compositions containing ergothioneine and vitamin E (Samples 1-1 to 1-5) were prepared. The obtained samples were subjected to sensory evaluation by three panelists skilled in sensory evaluation. Table 1 shows the (B) vitamin E content in samples 1-1 to 1-5 and the weight ratio of (B) vitamin E to (A) ergothioneine ((B)/(A)).
  • Each panelist placed the entire amount of the prepared sample (for example, 20 mg in the case of sample 1-1) directly on the tongue, and evaluated the intensity of bitterness derived from ergothioneine and the intensity of odor derived from vitamin E according to the following criteria. bottom.
  • bitterness derived from ergothioneine was evaluated on a scale of 1 to 5 (5 grades) according to the following criteria. As a reference point, the bitterness intensity of (A) ergothioneine (10 mg) was set at 5 points (control 1). The evaluation results of the three panelists were tabulated, and the average value (score) is shown in Table 1 as the evaluation results.
  • Example 2 By mixing the raw materials (A) and (C2) in amounts shown in Table 2, oral compositions containing ergothioneine and vitamin E (Samples 2-1 to 2-5) were prepared. The obtained samples were subjected to sensory evaluation by three panelists skilled in sensory evaluation. Table 2 shows the (B) vitamin E content in samples 2-1 to 2-5 and the weight ratio ((B)/(A)) of (B) vitamin E to (A) ergothioneine.
  • Each panelist placed the entire amount of the prepared sample (for example, 20 mg in the case of sample 2-1) directly on the tongue, and evaluated the intensity of bitterness derived from ergothioneine and the intensity of odor derived from vitamin E according to the following criteria. bottom.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Le but de la présente invention est de fournir : une composition orale contenant de l'ergothionéine ou un sel de celle-ci et de la vitamine E dans laquelle l'amertume résultant de l'ergothionéine ou d'un sel de celle-ci et l'odeur résultant de la vitamine E sont réduites au minimum ; et un procédé pour réduire au minimum l'amertume résultant de l'ergothionéine ou d'un sel de celle-ci et l'odeur résultant de la vitamine E. La présente invention concerne ainsi une composition orale qui contient un composant (A), qui est l'ergothionéine ou un sel de celle-ci, et un composant (B), qui est au moins un type de vitamine E, le rapport en poids ((B)/(A)) entre le composant (B) (en ce qui concerne la vitamine E) et le composant (A) (en ce qui concerne l'ergothionéine) étant compris entre 1 et 27.
PCT/JP2022/046218 2021-12-23 2022-12-15 Composition orale et procédé pour réduire au minimum l'amertume résultant de l'ergothionéine ou d'un sel de celle-ci et l'odeur résultant de la vitamine e WO2023120370A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021209562 2021-12-23
JP2021-209562 2021-12-23

Publications (1)

Publication Number Publication Date
WO2023120370A1 true WO2023120370A1 (fr) 2023-06-29

Family

ID=86902493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/046218 WO2023120370A1 (fr) 2021-12-23 2022-12-15 Composition orale et procédé pour réduire au minimum l'amertume résultant de l'ergothionéine ou d'un sel de celle-ci et l'odeur résultant de la vitamine e

Country Status (2)

Country Link
TW (1) TW202342009A (fr)
WO (1) WO2023120370A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012092085A (ja) * 2010-09-28 2012-05-17 Oriza Yuka Kk ササクレヒトヨタケ及びその抽出物を用いた皮膚光老化防止剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012092085A (ja) * 2010-09-28 2012-05-17 Oriza Yuka Kk ササクレヒトヨタケ及びその抽出物を用いた皮膚光老化防止剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Is "Hmm. Bad!" outdated? Introducing 3 delicious products and the characteristics of each ingredient of the ever-evolving "Aojiru"!", 1 September 2020 (2020-09-01), XP093074361, Retrieved from the Internet <URL:https://photo.daynight.jp/aojiru-osusume/> [retrieved on 20230816] *

Also Published As

Publication number Publication date
TW202342009A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
US8013013B2 (en) Formulation and delivery method to enhance antioxidant potency of vitamin E
CN111315239A (zh) 针对肌肉质量和/或肌肉量使用橄榄苦苷或姜黄素的组合物和方法
KR101761377B1 (ko) 닭 사료 및 그 제조방법
JP3392668B2 (ja) ゴマリグナン物質とビタミンｅ類の強化卵、強化卵の製造法、および強化卵に基づく健康食品
KR20160096294A (ko) 간기능개선과 간암, 숙취해소 및 피로회복 효과가 증진된 귀뚜라미 및 이를 함유하는 식품 조성물
WO2023120370A1 (fr) Composition orale et procédé pour réduire au minimum l&#39;amertume résultant de l&#39;ergothionéine ou d&#39;un sel de celle-ci et l&#39;odeur résultant de la vitamine e
JP2006347975A (ja) 循環器疾患予防改善のための経口用組成物
WO2020085155A1 (fr) Composition orale contenant une coenzyme q10 réduite, son procédé de production, procédé de prévention de décoloration et agent de prévention de décoloration
WO2023120376A1 (fr) COMPOSITION ORALE ET PROCÉDÉ POUR LIMITER L&#39;AMERTUME LIÉE À L&#39;ERGOTHIONÉINE ET L&#39;ODEUR LIÉE À L&#39;HUILE DE CÉRÉALE OU AU γ-ORYZANOL
WO2023120368A1 (fr) Composition orale et procédé pour limiter l&#39;amertume liée à l&#39;ergothionéine ou un sel de celle-ci et l&#39;odeur liée à l&#39;acide éicosapentaénoïque
WO2023120373A1 (fr) Composition orale et procédé pour limiter l&#39;amertume liée à l&#39;ergothionéine ou un sel de celle-ci et une odeur liée à l&#39;acide docosahexaénoïque
JP3602287B2 (ja) 魚類の脂質酸化防止方法及び魚類の脂質酸化防止剤
WO2024029393A1 (fr) Composition orale, et procédé inhibant l&#39;amertume provenant de l&#39;ergothionéine ou d&#39;un sel de celle-ci et l&#39;odeur désagréable provenant d&#39;une substance à teneur en céramide dérivé du lait
WO2023120367A1 (fr) Composition orale et procédé pour limiter l&#39;amertume liée à l&#39;ergothionéine
WO2023120378A1 (fr) Composition orale et procédé de suppression de l&#39;amertume dérivée de l&#39;ergothionéine ou du sel de celle-ci et d&#39;une odeur dérivée d&#39;acides arachidonique
JP4873605B2 (ja) 穀類由来の成分を有効成分とする血管新生阻害の作用を有する組成物
WO2024018955A1 (fr) Composition orale, et procédé inhibant l&#39;amertume provenant d&#39;une ergothionéine et le goût désagréable provenant d&#39;un composé glucosamine
WO2024029392A1 (fr) Composition orale, et procédé inhibant l&#39;amertume provenant de l&#39;ergothionéine ou d&#39;un sel de celle-ci
WO2022230491A1 (fr) Composition pour améliorer ou supprimer le déclin des fonctions rénales
WO2024018956A1 (fr) Composition orale, et procédé inhibant l&#39;amertume provenant d&#39;une ergothionéine ou d&#39;un sel de celle-ci et la mauvaise odeur provenant d&#39;un sulfate de chondroïtine ou d&#39;un sel de celui-ci
TWI834743B (zh) 含還原型輔酶ｑ１０之經口用組成物、其製造方法、變色抑制方法及變色抑制劑
WO2023063230A1 (fr) Composition contenant de la sésamine et de l&#39;ergothionéine ou un sel associé
WO2023120382A1 (fr) Composition orale et agent de capsule souple
JP3274677B1 (ja) 活性酸素消去能を有する卵とその生産方法
TW202412842A (zh) 口服組成物，及抑制來自麥角硫因之苦味及來自葡萄糖胺類化合物之異味之方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22911078

Country of ref document: EP

Kind code of ref document: A1